“neutralizing” Igs to SARS-CoV2 spike protein at median 29 days after 2nd mRNA vaccine dose (85%46% of 658 still w/o measurable Igs; 57% of 473 on IST). Low ORR!
Surrogate endpoint (protection)
When patients got their solid organ transplants

Significance for HSCT? https://twitter.com/jama_current/status/1390124154884657153

@CIBMTR/ @BMTCTN ongoing prospective observational trial to assess durability of SARS-CoV2 vaccine response at 6 mo.
includes patients ≤ 12 months from alloHCT, autoHCT, or CAR-T therapy
@Labcorp SARS-CoV-2 Semi-Quantitative Total Antibody

now
https://web.emmes.com/study/bmt2/protocol/2101_protocol/CIBMTR-07%20BMT%20CTN%202101_COVID%20Vaccine%20Study%20Plan_v2.0_20210416.pdf

@ASH_hematology/ @ASTCT #COVID19Vaccine FAQs for HSCT/CAR-T recipients:
Can offer vaccine ≥3 mo after HSCT
Efficacy
No preferred vaccine
≥14d b/w mRNA vaccine and other vaccines (COVID-19>routine vaccination)
Vaccines for transplant candidates

https://www.hematology.org/covid-19/ash-astct-covid-19-vaccination-for-hct-and-car-t-cell-recipients

Delay vaccine ≥90 days if prior mAb or convalescent plasma
testing with serology
Close contacts

supply now, should vaccination start sooner than 90 days post-HSCT?
@mini_kamboj @ZainabShd @JoshuaHillMD @tmhohl71 @JeffAuletta @Zee81582915 @AbidiMaheen @alpanaw @PergamIC